Navigate the Valsartan Recall
September 2018
The valsartan recall will continue to raise questions about how to switch to a different ARB or an ACE inhibitor.
The recalled products may have been contaminated with the probable carcinogen N-nitrosodimethylamine (NDMA) for as long as 4 years...possibly because of changes in how valsartan was made.
Reassure patients that cancer risk is very low. You can point out that FDA estimates 8,000 patients would need to take the recalled valsartan 320 mg daily for 4 years to possibly lead to one additional lifetime diagnosis of cancer.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote